ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ

Similar documents
Overview of Trasradial Approach for Coronary Angiography and Intervention. A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC

TRANSRADIAL CARDIAC CATHETERIZATION. Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013

ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΑΝΑΚΟΠΗΗ ΣΕΛΕΤΣΑΙΩΝ ΔΕΔΟΜΕΝΩΝ

Radial Artery Access Improving Outcomes and Decreasing Costs

Transradial vs. Transfemoral Access in STEMI: Should We Randomize?

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

Access Issues and Bleeding Complications

Bivalirudin Clinical Trials Update Evidence and Future Perspectives

Switching from femoral to radial access for coronary angiography in ACS

STEMI AND MULTIVESSEL CORONARY DISEASE

Is the role of bivalirudin established?

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Updated and Guideline Based Treatment of Patients with STEMI

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Cover Page. The handle holds various files of this Leiden University dissertation

CPORT E Trial. Atlantic C PORT

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization.

PCI Update Qesaria 2009

Belinda Green, Cardiologist, SDHB, 2016

PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS

How to manage ACS patients with Comorbidities? Patients with Renal Failure

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany

Cath Conference Kintur Sanghvi MD March 15, 2007

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

OBJECTIVES. New Twist To Old Disease: Cardiovascular Update /9/2017. Prevention Pre-operative Coronary Artery Disease

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

Transfemoral access (TFA) through the percutaneous

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

No conflict of interest to declare

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Columbia University Medical Center Cardiovascular Research Foundation

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Freedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Supplementary Online Content

Thrombolysis, adjunctive pharmacology and interventions

Approach to Multi Vessel disease with STEMI

Is there a real need for new agents to optimize efficacy/safety balance

Optimal Duration and Dose of Antiplatelet Therapy after PCI

Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe?

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Optimal lenght of DAPT in different clinical scenarios

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT

Trial Update- TOTAL. Jonathan Byrne

Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia

Clinical Lessons from BMC2-PCI

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

Angioplastica coronarica nel paziente anziano ad alto rischio emorragico

Case Challenges in ACS The Very Elderly in the Cath Lab

RIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study. Sanjit Jolly MD, MSc FRCPC

On admission Acute extensive anterior STEMI

Άγγελος Παπανικολάου MD, Ειδικευόμενος Καρδιολογίας, A Πανεπιστημιακή Καρδιολογική Κλινική, ΓΝΑ Ιπποκράτειο

Supplementary Table S1: Proportion of missing values presents in the original dataset

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

Transition from TF to TR Access in IO: Effect on Patient Radiation Exposure and Fluoroscopy Time

Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute

Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction

Timing of Surgery After Percutaneous Coronary Intervention

Optimal Duration of Dual Anti- Platelet Therapy. December 19, 2015

Pharmaco-Invasive Approach for STEMI

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Optimal antithrombotic therapy:

Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)

DECLARATION OF CONFLICT OF INTEREST

Is Cangrelor hype or hope in STEMI primary PCI?

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Ischemic Heart Disease: The 5 Most Important Trials in the Last Year

ST-Elevation MI: Update on Bivalirudin and DES

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

Do We Need Platelet Function Assays?

Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Transcription:

ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ ΓΙΔΝΔΡΓΔΙΑ ΠΡΩΣΟΓΔΝΟΤ ΓΙΑΓΔΡΜΙΚΗ ΣΔΦΑΝΙΑΙΑ ΠΑΡΔΜΒΑΗ ΑΠΟ ΣΗΝ ΚΔΡΚΙΓΙΚΗ ΑΡΣΗΡΙΑ Λάμπρος Κ. Μόσιαλος Γιεσθσντής Δπεμβατικός Καρδιολόγος ΓΝΘ «Παπαγεωργίοσ»

Patient characteristics 53 yo M presented to the ED with chest pain lasting 30 min. Heavy smoker ECG showed ST-e in II III avf V6 Given ASA, Prasugrel Radial access chosen

DIAGNOSTIC CorAngio Direct PPCI in RCA - TRA

DIAGNOSTIC CorAngio Direct PPCI in LAD - TRA

Patient characteristics 67 yo M with chest discomfort lasting 12 h NIDDM, Smoker ST-e in II III avf predominantly in III, ST-d in I avl V5 V6 Given ASA, Prasugrel Radial access.

Direct PPCI probable contribution Shortening of D2B time Prevention of artery spasm Reduced contrast administration Less fluoroscopy time More cost effective

TRA-PPCI in PAPAGEORGIOU CATH LAB 2012 2271 Overall cases 1585 Diagnostic 684 PCI. 553 TRA (81%) 109 Primary PCIs 81 TRA (74%)

KATANOMH PPCI ΜΔ ΒΑΗ ΣΗΝ ΟΓΟ ΠΡΟΠΔΛΑΗ

Why transradial approach for Primary PCI?

Mortality & Bleeding / Transfusion Doyle et al, JACC 2009; 53: 2019-27

SITES OF BLEEDING OVERALL NSTEMI STEMI JACC Vol. 55, No. 20, 2010 Transradial Approach for PCI May 18, 2010:2187 95

RIVAL Study: Subgroups: Primary Outcome Death, MI, Stroke or non-cabg major Bleed Overall Age <75 75 Gender Female Male BMI <25 25-35 >35 Radial PCI Volume by Operator 70 70-142.5 >142.5 Radial PCI Volume by Centre Lowest Tertile Middle Tertile Highest Tertile Diagnosis at presentation NSTE-ACS STEMI 0.25 Hazard Ratio (95% CI) 1.00 4.00 Radial better Femoral better p-value Interaction 0.786 0.356 0.637 0.536 0.021 0.025

Romagnoli et al. TCT 2011 RIFLE-STEACS study: Reduction in bleeding with TR access 30-day bleeding rate

STEMI RADIAL - results 30-day NACE p = 0.0028 11.0% 58% 4.6% p = 0.0001 7.2% 80% 1.4% 4.2% p = 0.7 3.5% Net Adverse Clinical Event (NACE) = MACE + major bleeding MACE = composite of death, myocardial infarction and stroke I Bernat TCT 2012

21 studies 8534 pts EuroIntervention 2012;8:501-510

Mortality in the TRA vs TFA EuroIntervention 201 2; 8:501-510

Ongoing Randomized Trials Comparing TRA-TFA RADIAL-CABG : 128 pts Diagnostic-PCI STEMI-RADIAL : 700 pts Acute MI SAFARI-STEMI : 1274 pts Acute MI MATRIX : 6800 pts ACS SAFE-PCI for WOMEN : 3000 pts Diagnostic-PCI ClinicalTrials.gov

LEARNING CURVE JACC Vol. 55, No. 20, 2010 Transradial Approach for PCI May 18, 2010:2187 95

LEARNING CURVE Procedural Failure for TRA 10% in the first 50 cases 3-4% after other 500 <1% only after 1000 Louvard Y. Am J Cardiol 2004 94:1177-80

CONCLUSIONS TRA is specially effective in high risk populations like old patients, AMI, patients treated with powerful anticoagulant or antiplatelet drugs. Modern interventional cardiologist should adopt TRA as first choise. The effectiveness of radial procedures might be linked to operator s expertise and a center s volume

ΕΥΦΑΡΙΣΤΩ

Meta-analysis 1:- Radial vs Femoral Agostoni et al, JACC 2004; 44: 349-56

Meta-analysis 2: Radial vs Femoral 23 studies included spanning 1993 2007 Major Bleeding: Radial: 0.5% (13 / 2390 pts) Femoral: 2.3% (48 / 2068 pts) OR: 0.27 (95% CI 0.16 0.45, p < 0.001) Trend towards reduced composite of death / MI / stroke OR: 0.71 (95% CI 0.49 1.01, p = 0.058) Trend towards reduced mortality OR 0.74 (95% CI 0.42 1.30, p = 0.29) Jolly et al, Am Heart J 2009; 157: 132-40)

MORTAL Study Access Site Odds Ratios (adjusted for baseline characteristics) for receiving a transfusion based on Radial vs Femoral access: 0.59 (95% CI 0.48 to 0.73), p < 0.001 Adjusted OR for mortality: TRA v TFA 30 day: 0.71 (95% CI 0.61 to 0.82) p < 0.001 1 year: 0.83 (95% CI 0.71 to 0.98) P < 0.001 If only non-transfused procedures analyzed, difference in mortality non-significant Supports hypothesis that mortality difference closely linked with need for transfusion Chase et al, Heart 2008; 94: 1019-1025

RIVAL (RadIal Vs femoral access for PCI) Study Design NSTE-ACS and STEMI (n=7021) Randomization 3831 (45%) pts were sub-study of OASIS-7 Trial Key Inclusion: Intact dual circulation of hand required Interventionalist experienced with both (minimum 50 radial procedures in last year) Radial Access (n=3507) Femoral Access (n=3514) Blinded Adjudication of Outcomes Primary Outcome: Death, MI, stroke or non-cabg-related Major Bleeding at 30 days Jolly S et al. published online Lancet April 4, 2011

RIVAL TRIAL Primary and Secondary Outcomes at 30 days Radial (n=3507) Femoral (n=3514) % p=0.50 3.7 4.0 p=0.90 3.2 3.2 Death, MI, Stroke, or non CABG Bleeding Death, MI or Stroke Jolly S published online at thelancet.com April 4, 2011

Cumulative analysis of major adverse cardiac events. EuroIntervention 201 2; 8:501-510

PCI and Bleeding

RIVIERA Study: Death / MI Montelescot et al, Int J Card 2008; 129(3): 379-387

RIVIERA Study: Bleeding Montelescot et al, Int J Card 2008; 129(3): 379-387

RADIAL APPROACH PENETRATION 60% in France 20% in Europe 1.5% in USA Louvard Y Ann Cardiol Angeiol (Paris) 2009;58:327-32

Choice of Site and Arterial Access The strongest multivariate predictors of femoral vascular complication during PCIs were: Age > 70 years Female sex Body surface area <1.6 m2 Renal failure or creatinine > 2mg/dl Emergent procedures Larger sheath sizes/iapb use Anticoagulation regimen: IIb/IIIa inhibitors and preprocedural use of thienopyridines Piper WD AHL 2003

Meta-analysis of Bleeding in ACS Hamon et al, EuroIntervention 2007; 3: 400-408

PROCERURAL and CLINICAL OUTCOMES after TRA PCI JACC Vol. 55, No. 20, 2010 Transradial Approach for PCI May 18, 2010:2187 95

MORTAL Study British Columbia Cardiac Registry used to evaluate patients who had undergone PCI from 1999-2005 Cross-referenced with Central Transfusion Registry to identify patients transfused within 10 days of PCI Objective: To determine association of arterial access site (radial vs femoral) with transfusion and mortality Chase et al, Heart 2008; 94: 1019-1025

RIVAL Study: Conclusions Overall Trans-radial approach was similar to Trans-femoral approach in terms of MACE with lower vascular complications in the radial group TRI had advantage over TFI in STEMI pts in having lower MACE and even lower mortality, perhaps largely driven by lower vascular/bleeding complications Radial approach had higher access site crossover without compromising PCI procedural success and was associated with higher radiation exposure The effectiveness of radial procedures might be linked to operator s expertise and a center s volume Jolly S et al. published online Lancet April 4, 2011

Radial PCI in STEMI - MACE Azmendi et al, Am J Card 2010; 106(2): 148-154

Major Femoral Bleeding Post-PCI Doyle et al, JACC Interventions 2008 ; 1: 202-9

Bleeding rates reduced with Bivalirudin, but are still 5% in STEMI Stone G, et al, NEJM 2008;358 : 2218-30

First Randomized Comparison of Elective PCI via TRA-TBA-TFA

First prospective multi-center randomized AMI-TRI trial Catheterization and Cardiovascular Interventions 59:26 33 (2003)

Meta-analysis in STEMI Patients MORTALITY MAJOR BLEEDING ACCESS SITE COMPLICATION MACE Mamas A. Heart 2012;98:303-311